CHICAGO, ILLINOIS--(Marketwire - June 02, 2008) - MethylGene Inc. (TSX: MYG) today announced preliminary data from two ongoing clinical studies with MGCD0103, a novel, isoform-selective histone deacetylase (HDAC) inhibitor, conducted in collaboration with Celgene Corporation and Taiho Pharmaceutical. Results from a Phase II study evaluating MGCD0103 as a single-agent in Hodgkin lymphoma (HL) (Trial 010) were reported in an oral presentation on Sunday, June 1st. A poster presentation describing data from a Phase I/II clinical trial evaluating MGCD0103 in combination with gemcitabine in pancreatic cancer (Trial 006) was reported today. The data from these studies were presented at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
